Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

121.92 +1.36 (+1.12%)
Streaming Delayed Price Updated: 2:51 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 519,985
Open 120.56
Bid (Size) 121.87 (100)
Ask (Size) 121.96 (100)
Prev. Close 120.56
Today's Range 120.50 - 122.69
52wk Range 78.20 - 132.60
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
News headline image
1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
Topics Supply Chain

Performance

YTD
+20.2%
+20.2%
1 Month
+4.5%
+4.5%
3 Month
+21.5%
+21.5%
6 Month
+11.8%
+11.8%
1 Year
+54.0%
+54.0%

More News

Read More
News headline image
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
From Incyte
Via Business Wire
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
Incyte (NASDAQ:INCY): High Growth Stock Slides on Q2 Beat but Steep Guidance Cut ↗
Via Chartmill
INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings ↗
Via Chartmill
INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup ↗
Via Chartmill
Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation ↗
Via Chartmill
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. ↗
Via Chartmill
News headline image
Incyte Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly
Via StockStory
News headline image
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Incyte
Via Business Wire
News headline image
What To Expect From Incyte’s (INCY) Q2 Earnings
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
From Incyte
Via Business Wire
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?
Via StockStory
Topics Stocks
News headline image
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
From Incyte
Via Business Wire
News headline image
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Via The Motley Fool
News headline image
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
News headline image
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
From Incyte
Via Business Wire
News headline image
1 Mid-Cap Stock to Research Further and 2 We Avoid
Via StockStory
Topics Economy
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗
Via Chartmill
News headline image
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down
Via StockStory
Topics Retirement
News headline image
2 Growth Stocks to Add to Your Roster and 1 We Avoid
Via StockStory
Topics Electric Vehicles
News headline image
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
From Incyte Biosciences Japan G.K.
Via Business Wire

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 121.92
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 08/10/26 02:51 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 27.12B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 27B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.